(l-r) Robert Fletcher; Mike Megna; Fritz Reinhart; Mayor Arthur Vigeant; LFB-USA President William Gavin; architect Jon Cocker; Meredith Harris, Marlboro Economic Development; Angus McQuilken, Mass. Life Sciences Center; and David Masiello, president of RP Masiello Construction / Daily News and Wicked Local Staff photo/Art Illman
Marlborough, MA – LFB USA recently broke ground on a new 65,000sf manufacturing and laboratory facility that will bring 50 new jobs to the region.
Located on vacant land on Crowley Drive, the $37 million manufacturing facility will, in part, be used for the early-stage processing of antithrombin, commonly known as ATryn.
William Gavin, LFB president; Fritz Reinhart; and other company officials were joined by Mayor Arthur Vigeant and Angus McQuilken, vice president of communications and marketing for Mass Life Sciences, for a brief groundbreaking ceremony.
Crews leveled the ground in the fall and began laying the foundation in April with the goal of opening late next summer, according to Reinhart.
Last year, city officials approved a tax increment financing deal with the company, paving the way for construction of the new facility. Throughout the course of the seven-year deal, the project is estimated to generate $711,360 in tax revenue for the city, and the company plans to bring 50 new jobs to the city by the end of the deal.
Gavin described Marlboro as a “perfect” location for LFB, which also has offices in Framingham and Charlton, due to proximity to transportation and a well-educated workforce. “It just fits what we need,” he said.
LFB is one of several life sciences companies to expand or move to Marlboro in the past few years. “Life sciences has become an important engine for the Massachusetts economy,” McQuilken said.
-more-
“This is our signature capital investment,” said Gavin. “It represents a real maturation of the company. We really need to scale this up for the market demand.”
ATryn is used to treat preeclampsia, a hereditary disorder that can cause blood clots, seizures and, in severe forms, maternal or infant death.
“We anticipated the need for that product will go up in the future,” said Fritz Reinhart, senior director of project management at LFB USA – a pharmaceutical company.
Other products will be developed in the future, said William Gavin, company president.
